Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
Euro Surveill. 2018 Feb;23(7). doi: 10.2807/1560-7917.ES.2018.23.7.18-00057.
The 2017/18 interim estimate of trivalent influenza vaccine effectiveness (VE) was 39% (95% confidence interval: 20-54) in Navarre. Compared with individuals unvaccinated in the current and five previous seasons, VE against influenza B was 41% for current and any prior doses, 67% for current vaccination only, and 22% for any prior doses, and 43%, 51% and 54%, respectively against influenza A(H3N2). This suggests moderate VE despite predominance of lineage mismatched influenza B.
2017/18 年三价流感疫苗效力(VE)的临时估计结果显示,在纳瓦拉(Navarre)地区的效力为 39%(95%置信区间:20-54)。与当前和过去五个季节未接种疫苗的个体相比,当前和之前任何剂量的流感 B 疫苗的 VE 为 41%,当前仅接种疫苗的 VE 为 67%,之前任何剂量的 VE 为 22%;而针对 A(H3N2)的流感病毒,当前和之前任何剂量的 VE 分别为 43%、51%和 54%。这表明,尽管存在流感 B 谱系错配,但疫苗仍具有中等效力。